Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of first dose of treatment.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device =< 28 days prior to registration
COHORT 1: Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\r\n* NOTE: Subjects who were treated on a clinical study of allogeneic stem cell transplant (alloHSCT) will be eligible if they are at least 3 months after allogeneic HCT and are at least 3 weeks (>21 days) off of all immune suppression and have no evidence of active GVHD (physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed). Subjects with prior alloHSCT will not be eligible for enrollment during the safety run in phase
COHORT 2: Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment for pre-existent myeloid disorder such as MDS or MPN
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medication
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study therapy
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of study registration
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks or 5 half-lives of the first dose of treatment, whichever is shorter
Has participated in a study of an investigational agent and has received study therapy or has used an investigational device within 28 days of administration of MK-1454.
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medication
Currently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation/randomization
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
Is currently participating and receiving study therapy or has participated and received study therapy in a study of an investigational agent, or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of first dose of treatment or used an investigational device within 4 weeks of the first dose of treatment.
EXCLUSION - PARTICIPANT: Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of first dose of treatment. \r\n* Individuals in the follow-up phase of a prior investigational study may participate as long as it has been 4 weeks since last dose of the previous investigational agent of device.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Participants must not be currently receiving study therapy or have participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving pembrolizumab or has participated in a study of an investigational agent and received pembrolizumab or used an investigational device within 4 weeks of the first dose of study treatment.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 28 days of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Is currently participating in and receiving study therapy, or has participated in a study of an investigational agent and received study therapy, or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy of an investigational agent and received study therapy within 2 weeks of the first dose of treatment; this 2 week washout period would not apply to investigational food ingredients
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of on-study date
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, or herbal/complementary oral or IV medicine within 2 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 28 calendar days of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device =< 28 days of registration
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first planned dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy with another investigational device or study drug or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of treatment
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device =< 4 weeks of the first dose of study drug
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of day 1
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigation device within 4 weeks of the first dose of treatment; subjects must also have recovered from associated therapy (i.e., to grade =< 1 or baseline) and from adverse events due to any prior therapy
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigation device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigation device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the initiation of SBRT
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational new drug and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving a study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the study drug administration
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment; an exception will be made for patients who have received CTL019 on experimental protocol; these patients will be eligible to enroll once progression of disease or failure to respond is documented by clinical or radiologic assessment
Is currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Currently receiving or has had treatment with an investigational agent or used an investigational device within 4 weeks of study day 1
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study drug or using an investigation device within 4 weeks of the first dose of treatment
Currently participating or has participated in a study of an investigational agent and received study therapy or received investigational device within 4 weeks prior to the first dose of study treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
REGISTRATION TO TREATMENT (STEP 1): Patient may not be currently participating and receiving study therapy or have participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy, or has participated in a study of an investigational agent and received study therapy, or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment
Currently participating and receiving study therapy, or have participated in a study of an investigational agent and received study therapy, or used an investigational device =< 4 weeks of registration
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm OR participated in a study of an investigational agent, received study therapy or used an investigational device =< 4 weeks prior to registration
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Currently participating and receiving treatment in another study, or participated in a study of an investigational agent and received treatment, or used an investigational device within 4 weeks of randomization
Is currently participating, or has participated in a study of an investigational agent and received study drug, herbal/complementary oral or IV medicine, or used an investigational device within 4 weeks of the first dose of study drug. Participants must also have recovered from associated therapy (i.e., to Grade ?1 or baseline) and from adverse events (AEs) due to any prior therapy.
Is currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study drug or used an investigational device within 4 weeks of treatment allocation
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
Currently participating in and receiving study therapy or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study medication
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of study drug.
Is currently participating in and receiving study therapy or has participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of study therapy
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Currently receiving or has received an investigational treatment as part of a study of an investigational agent or has used an investigational device within 4 weeks before randomization.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigational device within 4 weeks of the first dose of study drug. Participant must also have recovered from associated therapy (i.e., to Grade ?1 or baseline) and from adverse events due to any prior therapy
Is currently participating in or has participated in a clinical study and received an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatment
Patients currently participating and receiving study therapy or who have participated in a study of an investigational agent and received study therapy or used and investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medication
Participant is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab and CC-486
Currently participating in another study and receiving trial treatment, participated in a study of an investigational agent and received trial treatment within 4 weeks of the first dose of medication in this study, or used an investigational device within 4 weeks of the first dose of medication in this study.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study drug or using an investigation device within 4 weeks of the first dose of treatment
Currently participating and receiving study therapy, or participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of medication
Currently participating and receiving study therapy, or participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of study medication
Currently participating and receiving study therapy, or participated in a study of an investigational agent and received study therapy, or used an investigational device within 4 weeks of the first dose of study medication
Currently participating or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Currently participating and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy in a study of an investigational agent or has participated and received study therapy in a study of an investigational agent or has used an investigational device within 28 days of administration of MK-3475
Concurrent enrollment in another therapeutic investigational clinical study or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug
Is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment for another health-related problem
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Has participated in a study of an investigational agent and received study therapy or used an investigational device within 28 days of study start
Patient is premenopausal (medical ovarian suppression is allowed); is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 2 weeks of the first dose of treatment
Is currently participating and receiving study therapy for his/her advanced melanoma or has participated in a study of an investigational agent and received study therapy in the advanced melanoma setting
Currently participating and receiving study therapy (except lenvatinib for patients in cohort 2) or has participated in a study of an investigational agent and received study therapy within 4 weeks prior to registration
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks prior to enrollment .
Is currently participating in or has participated in a study of an investigational agent and is currently receiving study therapy or has participated in a study of an investigational agent and has received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Patients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study drug
Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.
Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study therapy
Participated in another investigational study (drug or device) within 4 weeks of first dose
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Currently participating in or has participated in a study of an investigational agent or using an investigational device =< 28 days prior to registration
Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 3 weeks of the first dose of MK-3475
Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of MK-3475
Is currently participating in or has participated in a study of an investigational agent or an investigational device within 4 weeks of the first dose of treatment.
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment\r\n* Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
Is currently participating in or has participated in a study of an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatment. Note: Subjects who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment
Patients who have participated in a study with an investigational agent or device within 2 weeks of initiation of treatment
Currently participating in a study of an investigational agent
Subjects participating in or who have participated in a study of an investigational agent or is using an investigational device within 4 weeks of the first dose of study treatment or have received any anti-cancer therapy, platinum-based chemotherapy, targeted, biological (including humanized antibodies), investigational, immunotherapy, or hormonal agent, within 4 weeks of the first dose of study treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 28 days of the first dose of study drug
Currently participating or has participated in a study of an investigational cancer therapy agent or using an investigational device within 28 days prior to study registration
Is currently participating in a study of an investigational anti-cancer agent.
Is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the first dose of trial treatment; the 30 day window should be applied to the last dose of an antineoplastic investigational agent or last use of an investigational device with antineoplastic intent
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment or 5 half-lives, whichever is shorter
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of pembrolizumab
Patients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of trial treatment
Is currently participating or has participated in a study of an investigational agent or using an investigational device
Currently receiving any other investigational agents, has participated in a study of an investigational agent, or use of an investigational device within 4 weeks of the first dose of pembrolizumab
Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of MK-3475
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Patients currently participating or has participated in a study with an investigational compound or device within 4 weeks of initial dosing with study drugs
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent (except glutamine) or using an investigational device within 4 weeks of the first dose of treatment or 5 half lives, whichever is shorter
Subject is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment
Is currently participating in a study of an investigational anti-cancer agent
Is currently participating in or has participated in a study of an investigational agent (except glutamine) or using an investigational device within 2 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Subject is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Currently participating or has participated in a study of an investigational agent or using an investigational device within 28 days of administration of MK-4166
Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study drug
Patients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 28 days of the first dose of study drug
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 14 days of the first dose of treatment;
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of study drug.
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating or has participated in any other any other investigational or therapeutic trial before or after chemoradiation.
Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the firs dose of study drug (a patient in the survival follow up phase of an investigational agent where no further treatment is expected is eligible)
Patients who have participated in a study with an investigational agent or device within 2 weeks of initiation of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks of the first protocol treatment
Patients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment; Note: participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent
Is currently participating in or has participated in any study of an investigational agent or using an investigational device within 4 weeks of transplant admission
Patient has participated in an investigational research study using an investigational agent within the last 30 days prior to screening
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to allocation, has had major surgery within 4 weeks or radiation therapy within 2 weeks prior to allocation, or who has not recovered (i.e., ? Grade 1 or to Baseline) from AEs due to prior treatment.
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization.
Currently participating or has participated in a study (treatment period only) of an investigational agent or used an investigational device within 28 days of enrollment
Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of study drug
Subject is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the first dose of study treatment
Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of administration of pembrolizumab
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of first dose of study drug
Currently participating or has participated in a study using an investigational antineoplastic agent or device within 30 days of first dose
Subject is currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent; and
Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of administration of study therapy
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or is or has been using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks (4 weeks for monoclonal antibodies) of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of registration. Subjects are not permitted to participate in another investigational drug study while being treated on this protocol.
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device 4 weeks since last dose of agent administration
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks of the radiation therapy
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of trial medication
Currently receiving treatment in a study of an investigational agent or using an investigational device <= 4 weeks prior to the first dose of trial medication
Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to randomization
Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study drug
Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of Study Day 1
Subjects participating in or who have participated in a study of an investigational agent or is using an investigational device within 4 weeks of the first dose of study treatment or have received any anti-cancer therapy, chemotherapy, targeted, biological (including humanized antibodies), investigational, immunotherapy, or hormonal agent, within 4 weeks of the first dose of study treatment
Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 4 weeks of the first dose of treatment in this current study.
Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug(s)
Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug(s)
Is currently participating in or has participated in a study of an investigational agent or using an investigational device.
Patients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to day 1
Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
Is currently participating in a clinical study and receiving an investigational agent and/or using an investigational device, or has participated in a clinical study and received an investigational agent and/or used an investigational device within 4 weeks prior to randomization.
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents
Participants may not be receiving any other investigational agents; patients may not be receiving any other treatment for their rectal cancer during study participation and within 30 days prior to study treatment
Participants may not be receiving any other study agents concurrently with the study drugs
Participants may not be receiving any other research study agents
Participants may not be receiving any other study agents for at least 7 days prior to enrollment
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents
Participants who are currently receiving other anticancer agents.
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents, and may not have received any other investigational agents within 6 months prior to study entry
Patients receiving any other study agents
Participants who are receiving any other study or off protocol anti-cancer agents
May not be receiving any other study agents
Participants may not be receiving any other study agents
PHASE I: Participants may not be receiving any other study agents within 2 weeks of initiating treatment
Participants may not be receiving any other study agents concurrently with the study drugs
Participants receiving any other study agents
Participants may not be currently receiving any other experimental agents
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents.
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents
Participants may not be receiving any other study agent
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents during the study or within 4 weeks of the start of the trial
EXPANSION COHORT ONLY: Participants may not be receiving any other study agents during the study or within 4 weeks of the start of the study
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents at the time of first treatment
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents or other types of cancer therapy while on this protocol except for disease progression
Participants may not be receiving any other study agents within 21 days prior to entry on the study
Participants may not be receiving any other study agents
Patients receiving any other study agents
Participants who are receiving any other investigational agents that might interact with study medication or influence the measurement of study outcomes
Patients receiving any other study agents
Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Currently receiving or have received any other investigational agent considered as a treatment for the primary neoplasm =< 21 days prior to registration
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm =< 21 days prior to registration
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm or used an investigational device =< 4 weeks from registration
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any investigational agent, that would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Currently receiving or have received any other investigational agent considered as a treatment for the primary neoplasm =< 28 days or within 4 half-lives (whichever is shorter) of the agent prior to registration
Receiving any other investigational agent, which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm; patients must be >= 2 weeks from prior anti-lymphoma therapy; the use of steroids and/or rituximab up to 1 week prior to registration for management of symptoms is allowed
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Currently receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent =< 4 weeks prior to registration which would be considered as treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent that would be considered a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Currently receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Patients who are receiving any other investigational agent(s)
Patients who are currently receiving any other investigational agent
Patient is currently receiving or has received another investigational agent within 4 weeks prior to day 1 of study
Patients may not be receiving any other concurrent investigational agents, or have received any investigational agent within four weeks of commencing this protocol.
Patients who are currently receiving another investigational agent are excluded
Patients may not be receiving any other investigational agent
Receiving any other agent which would be considered as a treatment for the lymphoma
Currently receiving any other investigational agent or received an investigational agent within last 30 days of study entry.
Patient is currently receiving or has received another investigational agent within 4 weeks prior to study day 1
Receiving other investigational agent concomitantly
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
Receiving any other investigational agent that would be considered as a treatment for the lymphoma
Patients who are currently receiving another investigational agent are excluded
Receiving any approved or investigational anti-cancer agent other than those provided for in this study
Participants who are receiving an investigational agent(s)
Patients receiving another investigational agent
Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days
Receiving any other investigational agents, or has received an investigational agent within the last 30 days
Patient is currently receiving or has received another investigational agent within 4 weeks prior to day 1 of study
Patients receiving any other investigational agent (s)
Receiving any other investigational agent
Patients who are currently receiving any other investigational agent
Patients must not be receiving any other investigational agent
Receiving other investigational agent
At least 21 days have passed since receiving any investigational agent at the time of registration
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
Currently receiving an investigational agent
Receiving or less than 21 days since receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent
PHASE I: Patients who are receiving any other investigational agent
PHASE II: Patients who are receiving any other investigational agent
Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days
Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days
Currently receiving any other investigational agents, or received an investigational agent within 3 weeks of the first dose of nintedanib
Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days
Patients who are receiving any other investigational agent
Receiving any other investigational agent which would be considered as a treatment for the lymphoma
Receiving any other investigational agent
Patient is receiving any other investigational agent
Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)
Patients must not be receiving any other investigational agent
Receiving any other investigational agent
Patients who were currently receiving any other investigational agent.
Patients receiving other investigational agent
Currently receiving another investigational agent
Receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent
Receiving another investigational agent (30 day wash-out required prior to first dose)
Patients that are receiving any other investigational agent
Receiving any investigational agent currently, or within 2 weeks of day 1 of treatment on this study
Patients receiving an investigational agent within 30 days before enrollment
Currently receiving a study therapy or if they had an investigational agent within 4 weeks at the time of enrollment.
Patients must not be receiving any other investigational agent
Patients may not be receiving any other investigational agent with therapeutic anticancer intent
Receiving any other investigational agents or receipt of another investigational agent within 4 weeks of study entry
Patients may not be receiving nor have received any other investigational agent =< 4 weeks prior to study registration
Patients who are receiving any other investigational agent
Patients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of 4 weeks is required
Receiving other investigational agent
Patients receiving other investigational agent
Patients receiving any other current investigational therapeutic agent.
Receiving any other investigational agent
Patients may not be receiving any other investigational agent with therapeutic anticancer intent
The participant is receiving any other investigational agent(s)
Patients receiving any other investigational agent(s)
Patients may not be receiving any other investigational agent
Receiving any other investigational agent
Receiving any approved or investigational anti-cancer agent other than those provided for in this study
Receiving erythropoietin stimulating agent
Receiving any agent classified as an antioxidant
Patient who is receiving investigational agent(s) as part of another clinical study at the time of screening or who anticipates receiving investigational agent(s) during their scheduled radiotherapy and concomitant daily temozolomide therapy (e.g. through the BMX001, MRZ 112, and BMX 209-548 studies)
Patient must not be receiving any other anti-cancer agent
The participant is receiving any other investigational agent(s).
The participant is receiving any other investigational agent(s).
Patients must not currently be receiving any other investigational agents
Patients who are currently receiving other anticancer agents
Subject is currently being treated with other investigational agents.
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Currently receiving any investigational agents within the previous six weeks or received any tumor vaccines within the previous 6 weeks
Currently receiving any other investigational agents
EXCLUSION - TREATMENT: Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks
Currently receiving any other investigational agents
EXCLUSION CRITERIA FOR REGISTRATION: Currently receiving any other investigational agents or systemic cancer therapy
TREATMENT EXCLUSION: Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Patients who are currently receiving or have previously received any other investigational agents within 3 weeks prior to entering the study
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents or received any within the past 28 days
Patients who are currently receiving any other investigational agents.
Subjects who are currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving investigational agents that are intended as treatments of recurrent GBM.
Currently receiving any other investigational agents
Currently receiving any investigational agents
Currently receiving any other investigational agents
Currently receiving any investigational agents
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Currently receiving any other investigational agents
TREATMENT: Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks
Currently receiving any other investigational agents that are intended as treatments of the relapsed tumor
Currently receiving any other investigational agents
Patients who are receiving concurrent chemotherapy, or who are currently receiving other investigational chemotherapeutic agents or concurrently receiving radiation
Currently receiving any other investigational agents
Currently receiving any investigational agents or received any tumor vaccines within the previous 6 weeks
Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Participants who are currently receiving any other investigational agents.
Currently receiving any other investigational agents, or exposure to any investigational drug or placebo within 4 weeks of study treatment
Currently receiving any other investigational agents
Currently receiving any other investigational agents.
Patients may not currently be receiving any other investigational agents for leukemia
Patients currently receiving other investigational agents
Currently receiving any investigational agents or have received any tumor vaccines within the previous six weeks
Currently receiving any other investigational agents
Receiving any investigational agents currently or within 30 days prior to study screening
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any investigational agents or have received any tumor vaccines within previous 4 weeks
Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Currently receiving any other active investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving investigational agents
Currently receiving any other investigational agents that are intended as treatments of GBM
Patients who are currently receiving any other investigational agents.
Currently receiving any investigational agents or registration on another therapy based trial
Currently receiving any other investigational agents
Participants who are currently receiving any other investigational agents
Receiving any other investigational agents currently, or within time limits specified above prior to study day 1
Other investigational agents currently or within 30 days prior to study enrollment
Patients who are currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents that are intended as treatments of recurrent GBM
Patients currently receiving other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Patients currently receiving any other investigational agents;
Currently receiving investigational agents in a clinical trial
Currently receiving investigational agents in a clinical trial
Participants who are currently receiving any other investigational agents or have received investigational agents within the past 3 months will be excluded
Patients may not be currently receiving any other investigational agents within 4 weeks of study registration
Patients must not currently be using other investigational agents
Have received any investigational agent with known anti-CMV activity within 30 days before initiation of study treatment or CMV vaccine at any time.
Have received any investigational agent with known anti-CMV activity within 30 days before initiation of study treatment or investigational CMV vaccine at any time.
Subjects who have received any anti-CMV therapy and investigational anti-CMV drugs at any time posttransplant.
Subjects who have had any anti-CMV vaccine at any time.
Any prior investigational CMV vaccine
Any prior investigational CMV vaccine
Any prior investigational CMV vaccine
RECIPIENT: Any prior investigational CMV vaccine
Has, is, or is planning (during the study) to participate in any study involving administration of a CMV vaccine or another CMV investigational agent
Participants who are receiving or have received any other investigational agents within 14 days of enrollment
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents during the proposed treatment cycle.
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational study agents or treatment for their cancer
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents.
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents within 21 days of the first dose of study drug
Participants who are receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
STRATUM A: Participants receiving any other investigational agents
STRATUM B: Participants receiving any other investigational agents
STRATUM C: Participants receiving any other investigational agents
Participants may not be receiving any other investigational agents targeting histiocytosis
Participants who are receiving any other investigational agents, or any other anti-cancer therapy during study treatment
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants may not have received any other investigational agents in the previous 3 months
Participants who are receiving any other investigational agents
Participants who are receiving any investigational agents are not eligible
Participants receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants may not be receiving any other investigational agents for treatment of their cancer
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants receiving any other investigational agents
Participants who are receiving any other investigational agents after ASCT
Participants may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents within 14 days before the first dose of study drug
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
PHASE II: Participants may not be receiving any other investigational agents
Participants may not be receiving any biologics or investigational agents within 3 weeks
Participants receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants may not be receiving any other investigational anticancer agents
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants who are receiving concurrent therapy with other investigational agents
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants receiving any other anti-cancer or investigational agents
Participants may not be receiving other investigational agents.
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants may not be receiving any other investigational agents within 30 days of enrollment or during this study
Participants who are receiving any other investigational agents
Research participants receiving any other investigational agents
Participants who are receiving any other investigational agents; participants who are receiving standard of care induction therapy on a clinical trial may be eligible after discussion with the overall principal investigator
Participants who are receiving any other investigational agents
Participants receiving any other investigational agents
Participants who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable
Participants may not be receiving any other investigational agents for treatment of GVHD or underlying disease for at least 7 days
Participants may not be receiving investigational agents
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents within past 3 months
Participants may not have received any other investigational agents in the previous 3 months
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents during the study
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants receiving other investigational agents
Participants who are receiving any other investigational agents